-
1 Comment
Biomark Diagnostics Inc is currently in a long term downtrend where the price is trading 12.9% below its 200 day moving average.
From a valuation standpoint, the stock is 93.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 90.1.
Biomark Diagnostics Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 71.1% to $-194K since the same quarter in the previous year.
Finally, its free cash flow fell by 165.0% to $-229K since the same quarter in the previous year.
Based on the above factors, Biomark Diagnostics Inc gets an overall score of 2/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| Industry | Diagnostics & Research |
| ISIN | CA09073K1084 |
| Sector | Healthcare |
| Beta | -0.52 |
|---|---|
| Market Cap | 14M |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | None |
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts. The company was incorporated in 2014 and is headquartered in Richmond, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 20B.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
